Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Lymphoma (DLBCL) Prognosis Panel

This panel computes five validated prognostic indices for Diffuse Large B-Cell Lymphoma (DLBCL) to support clinical decision-making at diagnosis: 1.

Evidence-based context for fast calculator use

Purpose:
Combined Classic IPI, NCCN-IPI, aaIPI, CNS-IPI, and R-IPI for Diffuse Large B-Cell Lymphoma.
Population:
patients whose clinical question requires the component models displayed in the combined panel
Factors:
Age, Ann Arbor Stage, ECOG Performance Status, Number of Extranodal Sites Involved, Patient Serum LDH, Lab Upper Limit of Normalfor LDH, Bone Marrow involvement, CNS involvement
HomeLymphoma (DLBCL) Prognosis Panel
Pin your most used calculators here by clicking the star in the dropdown.

Lymphoma (DLBCL) Prognosis Panel

U/L
U/L

Clinical Context & Background

This panel computes five validated prognostic indices for Diffuse Large B-Cell Lymphoma (DLBCL) to support clinical decision-making at diagnosis:
1. Classic IPI — The original and most widely used prognostic tool (1993). Recommended by ESMO as the standard reference for clinical trials.
2. NCCN-IPI — Enhanced model for the Rituximab era. Better discriminates high-risk (5y OS ~33%) and low-risk (5y OS ~96%) subgroups by refining age/LDH weighting and identifying high-risk extranodal sites. Confirmed as the best-performing clinical scoring system (Ruppert et al., Blood 2020).
3. Age-Adjusted IPI (aaIPI) — Recommended by ESMO and EHA 2025 guidelines. Uses only 3 factors (LDH, Stage, ECOG) enabling within-age-group comparisons and guiding treatment intensity.
4. CNS-IPI — Predicts risk of CNS relapse. EHA 2025 recommends assessment for all LBCL patients [III, A]. Critical for CNS prophylaxis decisions.
5. R-IPI — Simplified 3-tier model for the rituximab era. Included for compatibility with published clinical trial data.
Primary References:
The International NHL Prognostic Factors Project. NEJM 1993;329:987-994.
Zhou Z, Sehn LH, et al. Blood 2014;123(6):837-842.
Schmitz N, et al. JCO 2016;34(26):3150-3156.
Sehn LH, et al. Blood 2007;109(5):1857-1861.
Ruppert A, et al. Blood 2020;135(23):2041-2048.
ESMO Living Guidelines: DLBCL Staging & Risk Assessment.
EHA 2025 CPG: Large B-cell Lymphoma. HemaSphere 2025.
Formula Logic
Parallel DLBCL prognostic index calculations with separate component classifications; results are compared rather than averaged.

Reference Data

Risk GroupClassic IPI (5y OS)NCCN-IPI (5y OS)aaIPI ≤60y / >60y (5y OS)R-IPI (4y OS)CNS-IPI (2y CNS relapse)
Low0-1 (73%)0-1 (96%)0 (83% / 56%)0 (94%)0-1 (0.8%)
Low-Intermediate2 (51%)2-3 (82%)1 (69% / 44%)1-2 (79%)2-3 (3.9%)
High-Intermediate3 (43%)4-5 (64%)2 (46% / 37%)——
High4-5 (26%)6-8 (33%)3 (32% / 21%)3-5 (55%)4-6 (12%)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Lymphoma (DLBCL) Prognosis Panel when combined Classic IPI, NCCN-IPI, aaIPI, CNS-IPI, and R-IPI for Diffuse Large B-Cell Lymphoma.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Review every component result separately; if models disagree, verify inputs and follow the more cautious disease-specific pathway rather than averaging scores.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • A panel improves comparison but does not make component models interchangeable or create a new validated composite score.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients whose clinical question requires the component models displayed in the combined panel

How to apply this result

For a representative case, verify Age, Ann Arbor Stage, ECOG Performance Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

Myeloma Master Panel (R2-ISS & Frailty)Febrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

When should Lymphoma (DLBCL) Prognosis Panel be used?

Use it for patients whose clinical question requires the component models displayed in the combined panel when all required inputs and the intended clinical setting are confirmed.

Can Lymphoma (DLBCL) Prognosis Panel determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.